Early expansion and enhanced functionality of the product lineup

「In June 2026, we began rental sales in Japan of a new medical HAL lower-limb model that accommodates heights from 150cm to 190cm with a single unit and substantially improves ease of operation and operational efficiency, positioning it as a core model for accelerating the adoption of cybernics treatment. We plan to roll it out overseas in stages.」

「In June 2026, we began rental sales in Japan of a new medical HAL lower-limb model that accommodates heights from 150cm to 190cm with a single unit and substantially improves ease of operation and operational efficiency, positioning it as a core model for accelerating the adoption of cybernics treatment. We plan to roll it out overseas in stages.」

「In June 2026, we began rental sales in Japan of a new medical HAL lower-limb model that accommodates heights from 150cm to 190cm with a single unit and substantially improves ease of operation and operational efficiency, positioning it as a core model for accelerating the adoption of cybernics treatment. We plan to roll it out overseas in stages.」

「The Small Holter ECG Medical Vital Sensor Cyvis M100, part of this series, obtained medical-device certification in November 2024.」

「The smaller model of the medical-use HAL Lower-Limb Type obtained approval in January 2025 as a medical device for the already approved indications. Approval of the smaller model makes cybernics treatment available to patients approximately 100 cm to 150 cm tall, for whom use of the existing model, intended for patients approximately 150 cm and taller, had been difficult.」

「The company began selling the new HAL Lower-Back Type for Work Support model (LB06) in February 2026. It is designed to reduce workers' physical burden while improving safety and productivity.」

「In May 2024, the company obtained from the US FDA the world's first marketing approval for a small model of medical-use HAL® and approval to expand its indications to cerebral palsy, for patients aged 12 and older.」

「The photoacoustic imaging device Acoustic X uses an LED light-source system covered by the company's patents and enables real-time, high-resolution 3D imaging of peripheral blood vessels and blood without contrast agents and noninvasively. The company is pursuing medical-device status for the device as a next-generation medical imaging diagnostic system. Research is also underway at prominent overseas medical institutions and research facilities for a range of applications.」

「The next model in the Cyvis series, Cyvis-2, was submitted for medical-device certification in April 2023.」

「The photoacoustic imaging device Acoustic X uses an LED light-source system covered by the company's patents and enables real-time, high-resolution 3D imaging of peripheral blood vessels and blood without contrast agents and noninvasively. Research and development are being conducted under AMED's Medical-Engineering Collaboration Innovation Promotion Project (Development and Commercialization Program), while the company is pursuing medical-device status for the device as a next-generation medical imaging diagnostic system.」

「The first model in the Cyvis series, Cyvis-1, was registered as a medical device in April 2022, and trial provision to users began in May of the same year.」

「Research and development of Cyvis, a compact vital sensor intended to prevent and detect diseases such as myocardial infarction and cerebral infarction at an early stage, has been completed, and the company is proceeding with commercialization.」

「The HAL® single-joint type obtained medical-device certification in Europe in October 2019, then obtained certification as a medical device in Japan in July 2020. In August, it was approved for insurance coverage as an exercise-volume enhancement device for rehabilitation of cerebrovascular diseases and other conditions.」

「Since January 2020, the company has made users' physical function information visible by displaying in real time bioelectric signals from the neuromuscular system, the angle of trunk inclination and other information, enabling more effective exercise.」

「In July 2019, the company began selling the HAL® single-joint type ankle attachment as a new product designed to promote voluntary ankle movement and improve gait. In August 2019, it began selling the new HAL® Lower-Back Type for Care and Self-Support (BB04), which supports both caregivers and care recipients with a single unit.」

「In July 2019, the company began selling the HAL® single-joint type ankle attachment as a new product designed to promote voluntary ankle movement and improve gait. In August 2019, it also began selling the new HAL® Lower-Back Type for Care and Self-Support, which supports both caregivers and care recipients with a single unit. To improve usability, this new model features a control mode that can be used without attaching sensors and can be fitted in approximately 10 seconds.」

「Our group is working to realize Society 5.0/5.1 and a society with zero need for intensive care® by commercializing HAL® products for 1) medical use, aimed at improving and restoring patients' physical functions; 2) welfare use, aimed at supporting independent movement by older people and people with physical disabilities; and 3) work support, aimed at reducing the burden of heavy work at airports, construction sites, logistics facilities and other workplaces, as well as AI-equipped transport and cleaning robots, while pursuing further enhancements in functionality. The palm-sized vital sensor, an arteriosclerosis and electrocardiography device intended to prevent disease before it occurs, obtained medical-device approval in December 2018, and the company is preparing for general sales.」

「Our group is working to prevent and diagnose cardiovascular diseases such as myocardial infarction and stroke. It developed the palm-sized vital sensor VS-AS01, a compact device using an LED light source to detect arteriosclerosis and arrhythmia, the principal causes of these diseases, at an early stage, and obtained marketing approval from the Ministry of Health, Labour and Welfare as a medical device in December 2018. Vascular distensibility testing using this product became eligible for public health insurance coverage in January 2019. The company is currently preparing for mass production and sales.」

「The company is developing Cyin® as a sensing device that analyzes and processes various biological information, including bioelectric signals. It first applied Cyin®'s advanced sensing technology in the welfare sector and began general sales in September 2018 of Cyin® for welfare use, a communication device for people with severe disabilities that enables people with severe difficulty speaking or moving their bodies due to severe conditions such as neuromuscular diseases to operate various environmental control devices, including communication aids and nurse-call systems.」

「First, in April 2018, the company began sales activities for the HAL® Self-Support Lower-Limb Type Pro as the successor model to the HAL® Welfare Lower-Limb Type, with the aim of improving lower-limb function in people with lower-limb disabilities in the maintenance or community-living phase and those with reduced leg strength.」

「In January 2018, the company announced the new product Cyin™ for welfare use, developed using HAL® technology and enabling people with severe difficulty speaking or moving their bodies to operate various environmental control devices, including communication aids and nurse-call systems. In March 2018, it delivered the product to 11 patient and patient-support organizations that had cooperated in clinical research on HAL® and Cyin™ (donated by Daido Life Insurance Company) and is currently preparing for general sales.」

「In January 2018, the company announced that it would begin selling this spring the new cybernic interface Cyin™ for welfare use, developed using HAL® technology and enabling people with severe difficulty speaking or moving their bodies to operate various environmental control devices, including communication aids and nurse-call systems.」

「In October 2017, the company began selling the new HAL® Lower-Back Type for Self-Support, designed to maintain and improve trunk and lower-limb function in people with weakened legs and lower back. The HAL® single-joint type was selected in October 2017 for a physician-initiated clinical trial aimed at treating the acute phase of stroke, with Kyoto University Hospital serving as the lead research and development institution, under a subsidy program of the Japan Agency for Medical Research and Development (AMED). For the vital sensor, the company held preliminary consultations with PMDA (Pharmaceuticals and Medical Devices Agency) on an application for medical-device approval and was preparing to obtain medical-device status.」

「For the palm-sized vital sensor, an arteriosclerosis and electrocardiography device, the company has held preliminary consultations with PMDA (Pharmaceuticals and Medical Devices Agency) on an application for medical-device approval and is preparing to submit the application.」

「The company is also pursuing clinical research toward obtaining medical-device status for the ultra-lightweight, compact HAL® single-joint type, which supports the elbow and knee joints. For the palm-sized vital sensor, an arteriosclerosis and electrocardiography device, the company has begun preliminary consultations with PMDA (Pharmaceuticals and Medical Devices Agency) on an application for medical-device approval.」

「The company is also pursuing clinical research toward obtaining medical-device status for the ultra-lightweight, compact HAL® single-joint type, which supports the elbow and knee joints. For the palm-sized vital sensor, an arteriosclerosis and electrocardiography device, the company has begun preliminary consultations with PMDA (Pharmaceuticals and Medical Devices Agency) on an application for medical-device approval.」

「The company is also advancing procedures to obtain medical-device status for the HAL® Lower-Limb Self-Support Type (single-joint type) and the vital sensor.」

「To accelerate the rollout of these products, our group will not only design and develop new products but also work with users in the field to obtain feedback from actual operating environments and pursue further enhancements in functionality.」